e-SPACE CRM Program
PROGRAM
January 22-24, 2021
session 1
CRM highlights of the year
January 22 / 4.30 pm – 5.45 pm Singapore time – Chairs: Vlado Perkovic (Australia), Andrew Coats (Australia), Vijay Chopra (India)
January 23 / 6.45 pm – 8 pm Madrid time – Chairs: Giuseppe Rosano (UK), Stefan Anker (Germany)
DAPA-CKD – David Wheeler (UK)
EMPEROR-Reduced – Milton Packer (USA)
FIDELIO-DKD – George L. Bakris (USA)
SCORED & SOLOIST-WHF – Deepak L. Bhatt (USA)
Panel discussion
session 2
CRM important pathways: an update
January 22 / 6.45 pm – 8 pm Singapore time – Chairs: Chuan-Ming Hao (China), Stefan Anker (Germany), Gerasimos Filippatos (Greece)
January 23 / 4.30 pm – 5.45 pm Chicago time – Chairs: Shelley Zieroth (Canada), Marat Fudim (USA)
Fibrosis – Faiez Zannad (France)
Hypertension – Michael Böhm (Germany)
Autonomic dysfunction – Marvin A. Konstam (USA)
Metabolic changes in diabetes – Matthew R. Weir
Panel discussion
session 3
Treatment algorithms
January 22 / 8 pm – 9.15 pm Singapore time – Chairs: Stefan Anker (Germany), Manisha Sahay (India), Jian Zhang (China)
January 23 / 4.30 pm – 5.45 pm Madrid time – Chairs: Charles Herzog (USA), Giuseppe Rosano (UK)
HFpEF – John Cleland (UK)
HFrEF – Andrew J. S. Coats (Australia)
Kidney failure (on dialysis) with HF – David M. Charytan (USA)
CKD with HF – Nisha Bansal (USA)
Panel discussion
session 4
SGLT2 inhibition
January 22 / 4.30 pm – 5.45 pm Madrid time – Chairs: Peter Rossing (Denmark), Javed Butler (USA)
January 23 / 6.45 pm – 8 pm Chicago time – Chairs: Milton Packer (USA), Kamyar Kalantar-Zadeh (USA)
SGLT2 – heart or kidney drug? – Gerasimos Filippatos (Greece)
Using SGLT2 inhibitors – practical issues incl. side effect management – A. Cheng (Canada)
Management of diuretics – Patrick Rossignol (France)
What’s new on the horizon? – Stefan Anker (Germany)
Panel discussion
session 5
Other glucose-lowering therapeutic approaches
January 22 / 6.45 pm – 8 pm Madrid time – Chairs: Yehuda Handelsman (USA), José Zamorano (Spain)
January 24 / 4.30 pm – 5.45 pm Singapore time – Chairs: Juliana CN Chan (Hong Kong)
Metformin – Melanie J. Davies (UK)
Secretagogues – Giuseppe Rosano (Italy)
GLP-1 receptor agonists – Jennifer B. Green (USA)
DPP-4 inhibitors – Mark Cooper (Australia)
Panel discussion
session 6
Prevention and biomarkers
January 22 / 4.30 pm – 5.45 pm Chicago time – Chairs: Kirkwood F. Adams (USA); Kevin Damman (NL)
January 24 / 6.45 pm – 8 pm Singapore time – Chairs: Stephan von Haehling (Germany), Gerasimos Filippatos (Greece)
Assessment of kidney function in heart failure – Jeffrey Testani (USA)
Use of natriuretic peptide for patients with heart failure and kidney disease – Jim Januzzi (USA)
Use of troponin in kidney disease and heart failure – Lori B. Daniels (USA)
Assessment of volume status – Maria Rosa Costanzo (USA)
Panel discussion
session 7
Emerging treatment approaches for HF
January 22 / 6.45 pm – 8 pm Chicago time – Chairs: Mikhail N. Kosiborod (USA), Anita Deswal (USA)
January 24 / 4.30 pm – 5.45 pm Madrid time – Chairs: Marco Metra (Italy), Purva Sharma (USA), Gerasimos Filippatos (Greece)
Potassium binders – Javed Butler (USA)
Solutions for FMR and TR (valve insufficiency) – Horst Sievert (Germany)
New cardiovascular devices – from neurostimulation to ultrafiltration – William T. Abraham (USA)
Mechanical circulatory support – Lynne W. Stevenson (USA)
Panel discussion
session 8
Arrhythmias in kidney disease
January 23 / 4.30 pm – 5.45 pm Singapore time – Chairs: Der-Cherng Tarng (Taiwan), Vijay Chopra (India), Cihan Ay (Austria), John Atherton (Australia)
January 24 / 4.30 pm – 5.45 pm Chicago time – Chairs: Mintu Turakhia (USA), Catherine Clase (Canada)
AF in kidney disease and its treatment – Gregory Y. H. Lip (UK)
SCD in kidney disease and its treatment – Wojciech Zareba (USA)
Stroke prevention in patients with AF and CKD – Wolfgang C. Winkelmayer (USA)
Arrhythmias in diabetic kidney disease: a cardiology perspective – Cecilia Linde (Sweden)
Panel discussion
session 9
HFpEF
January 23 / 6.45 pm – 8 pm Singapore time – Chairs: Andrew Coats (Australia), Yuhui Zhang (China)
January 24 / 6.45 pm – 8 pm Madrid time – Chairs: Stefan Anker (Germany), Fausto Pinto (Portugal)
Diagnosis – Kavita Sharma (USA)
HFpEF in CKD – W. H. Wilson Tang (USA)
Treatment part 1 – Drugs – John J. V. McMurray (UK)
Treatment part 2 – Devices – Gerd Hasenfuß (Germany)
Panel discussion
session 10
Anemia and iron deficiency
January 23 / 8 pm – 9.15 pm Singapore time – Chairs: Angela Webster (Australia), Andrew Coats (Australia), Stefan Anker (Germany)
January 24 / 6.45 pm – 8 pm Chicago time – Chairs: Kamyar Kalantar-Zadeh (USA), Angela Webster (Australia), Javed Butler (USA)
Iron deficiency in CKD and HF – Adrian Hernandez (USA)
AFFIRM-AHF: more insights – Piotr Ponikowski (Poland)
IV iron and ESAs in CKD – Iain Macdougall (UK)
HIF PHIs: effects on renal anemia and CV outcomes – Adeera Levin (Canada)
Panel discussion
Organized by
PROGRAM e-SPACE
